

Characteristics of Cytosolic Calcium-Independent Phospholipase A₂ Isolated from Rat Liver

Jong Hak Won, Doe Sun Na[†], Hae Jin Rhee[†] and Young Min Park*

Department of Biology, College of Natural Science, Sungkyunkwan University, Suwon 440-746, Korea

[†]Department of Biochemistry, College of Medicine, University of Ulsan, Seoul 138-040, Korea

Received 6 November 1998, Accepted 24 November 1998

A calcium-independent phospholipase A₂ (iPLA₂) was identified from the cytosolic fraction of rat liver cells. On gel filtration chromatography, the iPLA₂ activity was eluted as broad peaks of 150 to 500 kDa. The enzyme was maximally active at pH 7.5, retained 75% of its original activity after heating at 50°C for 5 h, and was inhibited by Ca²⁺, Mg²⁺, and Zn²⁺ ions, but was not affected by Na⁺ and K⁺ ions. The enzymatic activity was increased up to 150% by 1 to 4 mM DTT and was inhibited up to 25% by 0.1 to 1 mM PMSF. The iPLA₂ activity had preference for the head group of phospholipids, where phosphatidylethanolamine was preferred to phosphatidylcholine. The results suggest that the iPLA₂ may be a novel enzyme distinct from the previously reported iPLA₂s.

Keywords: Ca²⁺-independent PLA₂, Enzyme activity, Rat liver.

Introduction

Phospholipase A₂ (PLA₂, EC 3.1.1.4) is a large superfamily of distinct enzymes (Dennis, 1997) which play important roles in cellular processes involving phospholipid digestion and metabolism, such as inflammation and signal transduction (Dennis *et al.*, 1991). PLA₂ hydrolyzes the acyl ester bond at the sn-2 position of membrane phospholipids and produces free fatty acids and lysophospholipids, the precursors of potent lipid mediators such as leukotrienes, prostaglandins, and platelet activating factor (Samuelsson *et al.*, 1987; Sirois, 1987; Sturk *et al.*, 1989; Dennis, 1994; Tischfield, 1997). Consequently,

PLA₂ activation has been postulated to contribute to the pathophysiology of inflammation and tissue injury in various disease states.

Based on the biochemical properties and structural features, the PLA₂ superfamily proteins can be classified into three main kinds: the Ca²⁺-dependent secretory enzymes (sPLA₂), the Ca²⁺-dependent cytosolic enzymes (cPLA₂), and the Ca²⁺-independent cytosolic enzymes (iPLA₂) (Dennis, 1997). sPLA₂s are characterized by their small sizes of 13 to 18 kDa, high disulfide content, and conserved three-dimensional structures. These enzymes require millimolar concentrations of Ca²⁺ for their maximal activity and do not have specificity for the fatty acid in the sn-2 position of phospholipids (Heinrikson *et al.*, 1977; Dennis, 1983; Renetseder *et al.*, 1985). cPLA₂s have apparent molecular weights of 70 to 100 kDa (Bennett *et al.*, 1990; Kim and Bonventre, 1993), require submicromolar levels of Ca²⁺ for activation (Kim *et al.*, 1991), and preferentially hydrolyze the arachidonic acid at the sn-2 position of phospholipids (Clark *et al.*, 1990).

iPLA₂s do not require Ca²⁺ for their maximal activities. iPLA₂ enzymes have been shown to be widely distributed and ubiquitously expressed in most mammalian tissues, underlining their potential importance in cellular functions (Ackermann and Dennis, 1995; Balsinde and Dennis, 1997). Only a few iPLA₂s have been purified and characterized from mammalian tissues, and the structures and mechanisms of iPLA₂s are still largely unknown. In this contribution, we have identified an iPLA₂ from rat liver and characterized its properties.

Materials and Methods

Chemicals DEAE-Sephacel, Sephacryl S-300, and Heparin Sepharose CL-6B were purchased from Pharmacia (Uppsala, Sweden). Arachidonic acid, dithiothreitol (DTT), phenylmethylsulphonyl fluoride (PMSF), and fatty acid-free

* To whom correspondence should be addressed.

Tel: 82-331-290-7008; Fax: 82-331-290-7015

E-mail: ympark@yurim.skku.ac.kr

bovine serum albumin (BSA) were purchased from Sigma (St. Louis, USA). 1-Acyl-2-[1-¹⁴C]-arachidonyl-sn-glycerol-3-phosphatidylethanolamine (55 mCi/mmol, 2-AA-PE), and 1-stearoyl-2-[1-¹⁴C]-arachidonyl-sn-glycerol-3-phosphatidylcholine (55 mCi/mmol) were purchased from Amersham (Buckinghamshire, UK). L-1-palmitoyl-2-[1-¹⁴C]-arachidonyl-sn-glycerol-3-phosphatidylcholine (55 mCi/mmol) was purchased from New England Nuclear (Boston, USA).

PLA₂ activity assay Enzymatic activity was assayed using 2-AA-PE unless otherwise specified. Liposomes were prepared by sonication as previously described (Kim *et al.*, 1991; Huh *et al.*, 1998). The reaction mixture (200 μ l final volume) contained 75 mM Tris-HCl (pH 7.5), 4 mM EGTA, 1 mg/ml fatty acid-free BSA, 0.5 nmol 2-AA-PE (60,500 dpm). The reactions were carried out at 37°C for 60 min and stopped by adding 600 μ l of methanol:chloroform (2:1 v/v), 200 μ l of chloroform, and 66 μ l of distilled water. The lipid was extracted by the method of Bligh and Dyer (1959) and the organic solvent was evaporated using a Speed Vac evaporator (Savant, Holbrook, USA). The lipid was resuspended in chloroform, supplemented with cold arachidonic acid, and separated on a TLC plate (silica gel F254; Merck, Darmstadt, Germany) using petroleum ether:ethyl ether:acetic acid (80:20:1, v/v/v) as the developing solvent. Arachidonic acid spots were visualized by I₂ spray, cut out, and the radioactivity was counted with a liquid scintillation counter.

Partial purification of cytosolic Ca²⁺-independent PLA₂ All purification steps were performed at 4°C. Rat liver (100 g) was minced into small pieces with sharp surgical scissors and blood was removed by washing with homogenization buffer (50 mM Tris-HCl, pH 7.4, 150 mM KCl, 3 mM MgCl₂, 1 mM DTT, 0.1 mM EDTA) containing 0.15 M sucrose. It was then homogenized in 4 vol of ice-cold homogenization buffer using a Polytron homogenizer. The homogenate was centrifuged at 20,000 \times g for 30 min and the supernatant was subsequently centrifuged at 100,000 \times g for 60 min to separate the cytosolic and microsomal fractions. The supernatant (cytosol) was filtered through glass wool and concentrated by ultrafiltration using an Amicon (Beverly, USA) YM-30 membrane. The cytosol was loaded onto a DEAE-Sephacel column (5 \times 30 cm) pre-equilibrated with buffer A (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 10% glycerol) and eluted with a linear salt gradient from 0 to 0.5 M NaCl in buffer A at a flow rate of 2 ml/min. The active fractions were combined, concentrated by ultrafiltration, and loaded onto a Heparin Sepharose CL-6B column (2.5 \times 20 cm) pre-equilibrated with buffer B (25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 0.1 M NaCl, 10% glycerol). The column was eluted with a linear salt gradient from 0.1 to 1.5 M NaCl in buffer B at a flow rate of 0.5 ml/min. The active fractions were pooled, concentrated, and loaded onto a Sephacryl S-300 column (2.5 \times 100 cm) pre-equilibrated with buffer C (25 mM Tris-HCl, pH 7.7, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 10% glycerol). The column was eluted with buffer C at a flow rate of 0.6 ml/min. The active fractions were pooled and frozen at -80°C until use.

Molecular weight estimation and determination of protein concentration Molecular weight estimation of iPLA₂ was

carried out by Sephacryl S-300 column chromatography using apoferritin (443 kDa), amylase (200 kDa), alcohol dehydrogenase (150 kDa), and BSA (66 kDa) as molecular weight standards. Protein concentration was determined by the methods of Bradford (1976) with BSA as the standard.

Results

Partial purification of iPLA₂ from rat liver When the cytosolic proteins were separated by DEAE-Sephacel column chromatography with a salt gradient, most of the iPLA₂ activity was eluted as a single peak between 0.2 and 0.3 M NaCl (Fig. 1A). Fractions with major activity were pooled, concentrated, and loaded onto a Heparin Sepharose CL-6B column. The iPLA₂ activity was detected in the flow-through fractions (Fig. 1B), indicating that iPLA₂ did not bind to the Heparin Sepharose CL-6B column. The active fractions were pooled, concentrated, and loaded onto a Sephacryl S-300 column. Four peaks of iPLA₂ activity appeared as a broad peak of 150 to 500 kDa (Fig. 1C). Figure 1D shows the effects of Ca²⁺ and EGTA on the iPLA₂ activity of the four peak fractions. All showed iPLA₂ activity in the presence of EGTA, and all were inhibited by 4 mM Ca²⁺ ion. Peak IV was used for characterization of the enzymatic properties.

Characterization of iPLA₂ from rat liver

Optimum pH: The optimum pH for the partially purified iPLA₂ was estimated to be pH 7.5 (Fig. 2).

Thermal stability: The temperature effect on the iPLA₂ activity was determined by measuring the activity after incubation for 10 min at various temperatures. After incubation at temperatures between 20 and 50°C, the enzyme was fully active, but it dramatically lost activity at 60°C, and no activity remained if incubated at 70°C (Fig. 3A). The thermal stability of the enzyme at 50°C was determined at various times after incubation. The activity increased to 150% after incubation for 30 min, and 75% of the initial activity remained after 5 h incubation (Fig. 3B).

Effects of metal ions: Effects of various metal ions on the iPLA₂ activity were examined in the presence of 1 mM metal ions. Na⁺ and K⁺ ions had no effects. The enzyme was partially inhibited by Ca²⁺ and Mg²⁺ ions, and completely inhibited by Zn²⁺ ion (Table 1).

Figure 4 shows the dependence of the iPLA₂ activity on Ca²⁺ and Zn²⁺ ions. The enzyme activity was similar in the absence of and at low Ca²⁺ concentrations of between 10⁻⁷ and 10⁻⁴ M; however, the activity decreased to 68% of its original activity at high Ca²⁺ concentrations above 1 mM (Fig. 4A). The enzyme activity was highly sensitive to the concentration of Zn²⁺ ion. The activity decreased with increasing Zn²⁺ concentration and dropped to zero at concentrations above 1 mM (Fig. 4B).




Fig. 1. Column chromatography profiles for purification of iPLA₂ from rat liver. A. DEAE-Sephacel ion-exchange, B. Heparin-Sepharose CL-6B, and C. Sephacryl S-300 column chromatography profiles. The enzyme activity in each fraction was assayed using 1-acyl-2-arachidonoyl-phosphatidylethanolamine (2-AA-PE) as the substrate. Composition of the assay mixtures was as in Materials and Methods. D. Effect of Ca²⁺ on the PLA₂ activity of peak fractions obtained from Sephacryl S-300 chromatography. PLA₂ activity was assayed in the presence of 4 mM EGTA or 4 mM Ca²⁺. The data shown are the average of three experiments.




Fig. 2. Effects of pH on iPLA₂ activity. The peak IV fraction from Sephacryl S-300 chromatography was assayed using the reaction mixture containing 4 mM EGTA, 1 mg/ml fatty acid-free BSA, and 0.5 nmol 2-AA-PE in 75 mM Tris-HCl buffers at various pH values. Non-specific hydrolysis at each pH was undetectable.

Effect of DTT and PMSF: The enzyme activity decreased to 25% as the concentration of PMSF increased from 0.1 to 1 mM and increased up to 150% by 1 to 4 mM DTT (Fig. 5).

Table 1. Effects of various metal ions on the iPLA₂ activity.

Metal ions	Relative activity (%)
EDTA	100.0 ± 2.4
NaCl	93.1 ± 0.6
KCl	104.0 ± 0.4
CaCl ₂	64.5 ± 4.1
MgCl ₂	78.4 ± 11.2
ZnCl ₂	0.0

The peak IV fraction from Sephacryl S-300 chromatography was assayed with the indicated metal ions. Concentration of metal ions was 1 mM in all cases.

Substrate specificity and kinetic parameters: The substrate specificity of the enzyme was analyzed by using different phospholipids (Table 2). Phosphatidylethanolamine (2-AA-PE) was hydrolyzed at about 5-fold the rate of phosphatidylcholine. At the sn-1 position, the enzyme preferred palmitic acid rather than stearic acid.

The substrate kinetics of the enzyme were determined using 2-AA-PE as the substrate (Fig. 6). A Lineweaver-Burk plot gave an apparent K_m value of 45 μ M and a V_{max} of about 160 pmol/min/mg.




Fig. 3. Thermal stability of iPLA₂ activity. A. The peak IV fraction obtained from Sephacryl S-300 chromatography was incubated for 10 min at the indicated temperature and was then assayed for iPLA₂ activity. B. The peak IV fraction was incubated at 50°C for the indicated times and then assayed for iPLA₂ activity.

Table 2. Substrate specificity of the iPLA₂.

Substrate	Relative activity (%)
1-Palmitoyl-2-arachidonoyl-PC	20.8 ± 8.2
1-Stearoyl-2-arachidonoyl-PC	14.2 ± 1.2
1-Acyl-2-arachidonoyl-PE	100.0 ± 1.8

The peak IV fraction from Sephacryl S-300 chromatography was assayed with the indicated substrates.

Discussion

Although iPLA₂ activities have been found in various mammalian tissues, only a few have been purified and characterized. They have different molecular weights,




Fig. 4. Effects of Ca²⁺(A) and Zn²⁺(B) on iPLA₂ activity. The peak IV fraction obtained from Sephacryl S-300 chromatography was assayed with various concentrations of Ca²⁺ or Zn²⁺ at pH 7.5.

substrate specificities, and optimum pHs, indicating the diversity of iPLA₂s. In this study, we identified a new form of iPLA₂ from a cytosolic fraction of rat liver. The iPLA₂ activity was eluted as a broad peak of 150 to 500 kDa from a gel filtration column. It was maximally active at pH 7.5 and thermally stable. The activity was highest in the absence of Ca²⁺, partially inhibited by Ca²⁺ or Mg²⁺, and strongly inhibited by Zn²⁺. The enzyme was inhibited by PMSF but not by DTT.

When DEAE-Sephacel column chromatography was performed, the total iPLA₂ activity in the eluent decreased to 10% of the loaded activity (data not shown). A similar phenomenon has previously been observed during purification of iPLA₂ from rat brain using Phenyl Sepharose column chromatography (Yoshihara and




Fig. 5. Effects of PMSF (A) and DTT (B) on iPLA₂ activity. The peak IV fraction obtained from Sephacryl S-300 chromatography was assayed with various concentrations of PMSF or DTT at pH 7.5.




Fig. 6. Lineweaver-Burk plot of iPLA₂ activity. The peak IV fraction obtained from Sephacryl S-300 chromatography was assayed at various concentrations of 2-AA-PE.

Watanabe, 1990). The loss of activity was speculated to be due to the dissociation of activator or cofactor from the enzyme; however, the regulatory factors have not been identified to date. This may be the case with the iPLA₂ from this study since the iPLA₂ activity was partially restored by adding the other fractions with no iPLA₂ activity (Yoshihara and Watanabe, 1990).

The apparent size of 200 to 500 kDa (Fig. 1C) might not represent the true molecular weight and may arise due to self-association or association with other proteins. Recent reports have suggested that different molecular masses or multimeric forms of iPLA₂s exist in various cells. For example, a 40 kDa iPLA₂ from myocardial tissue and pancreatic islets was associated with a 400 kDa phosphofructokinase (Hazen and Gross, 1993; Ramanadham *et al.*, 1996), and a 80 kDa iPLA₂ from the P388D1 macrophage cell line was associated with a 330 kDa protein (Ackermann *et al.*, 1994). The iPLA₂ from CHO cells and pancreatic islets have been shown to possess eight ankyrin repeats, which may mediate self-aggregation or interaction with other proteins (Ma *et al.*, 1997; Tang *et al.*, 1997; Larsson *et al.*, 1998).

The inhibition of iPLA₂ by divalent ions is quite unexpected. In the case of Ca²⁺-dependent sPLA₂, Zn²⁺ inhibits the enzyme by replacing Ca²⁺, which is necessary for its activity (Mezna *et al.*, 1994). Since iPLA₂ does not require Ca²⁺ for the activity, the mechanism by which divalent ions inhibit iPLA₂ activity is intriguing and needs detailed investigation. It is important to know whether other iPLA₂s are also inhibited by divalent ions. It is worth mentioning that even though Ca²⁺ is not required for iPLA₂ activity there must in fact be Ca²⁺ binding site(s).

The dependence of the enzymatic activity on PMSF suggests that the iPLA₂ has a serine residue which is essential for the catalytic reaction. This is consistent with the reports that the iPLA₂ sequences deduced from the cDNA of CHO cells and human B-cells contain the GX SXG motif which is commonly found in other lipases (Tang *et al.*, 1997; Larsson *et al.*, 1998).

The iPLA₂ has characteristics that distinguish it from previously identified PLA₂s. It is different from sPLA₂ on the following points: high molecular weight, the independence of Ca²⁺, insensitivity to DTT, inhibition by PMSF, and low affinity to Heparin-Sepharose resin. cPLA₂ has an alkaline pH optimum and requires micromolar concentrations of Ca²⁺ for activity.

Some biochemical properties of the iPLA₂ activity from rat liver, including insensitivity to DTT and Ca²⁺-independence for activity, are found among other iPLA₂s. Myocardial iPLA₂ has a molecular weight of 40 kDa, an optimum pH of 6.4, and plasmalogen selectivity (Hazen *et al.*, 1990). The iPLA₂ from P388D1 macrophage has a molecular weight of 80 kDa and an optimum pH of 7.5 (Ackermann *et al.*, 1994). Both of these appeared to be associated with high molecular weight complexes. The

rabbit kidney iPLA₂ has a molecular weight of 28 kDa, an optimum pH of 8.0, and plasmalogen selectivity (Portilla and Dai, 1996). Recently, 58 kDa and 15 kDa acidic-pH optimum iPLA₂s were purified from rat brain (Thomson and Clark, 1995) and lung (Wang *et al.*, 1994), respectively. A high molecular weight iPLA₂, 200 to 500 kDa, has been partially purified from rat brain (Yoshihara and Watanabe, 1990). This enzyme displayed Ca²⁺-concentration dependence similar to the rat liver iPLA₂ in this study. However, the iPLA₂ from rat brain has an alkaline pH optimum: the enzyme activity was four times higher at pH 9.0 than at pH 7.5. The iPLA₂ activity from this study was lower at pH 9.0 than at pH 7.5.

In conclusion, we have identified an iPLA₂ from rat liver. Characterization of its properties revealed that this enzyme may be a novel one.

Acknowledgment This study was supported in part by a grant (#HMP-98-B-2-0007) from the Good Health R&D Project of the Korean Ministry of Health & Welfare.

References

- Ackermann, E. J. and Dennis, E. A. (1995) Mammalian calcium-independent phospholipase A₂. *Biochim. Biophys. Acta* **1259**, 125–136.
- Ackermann, E. J., Kempner, E. S. and Dennis, E. A. (1994) Ca²⁺-independent cytosolic phospholipase A₂ from macrophage-like P388D1 cells. *J. Biol. Chem.* **269**, 9227–9233.
- Balsinde, J. and Dennis, E. A. (1997) Function and inhibition of intracellular calcium-independent phospholipase A₂. *J. Biol. Chem.* **272**, 16069–16072.
- Bennett, C. F., McCarte, A. and Crooke, S. T. (1990) Purification and characterization of a soluble phospholipase A₂ from guinea pig lung. *Biochim. Biophys. Acta* **1047**, 271–283.
- Bligh, E. G. and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37**, 911–917.
- Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**, 248–254.
- Clark, J. D., Milona, N. and Knopf, J. L. (1990) Purification of a 110-kilodalton cytosolic phospholipase A₂ from the human monocytic cell line U937. *Proc. Natl. Acad. Sci. USA* **87**, 7708–7712.
- Dennis, E. A. (1983) in *The Enzymes*, 3rd ed., Boyer, P. D. (ed.), Vol. 16, pp. 307–353, Academic Press, New York.
- Dennis, E. A. (1994) Diversity of group types, regulation, and function of phospholipase A₂. *J. Biol. Chem.* **269**, 13057–13060.
- Dennis, E. A. (1997) The growing phospholipase A₂ superfamily of signal transduction enzymes. *TIBS* **22**, 1–2.
- Dennis, E. A., Rhee, S. G., Billah, M. M. and Hannun, Y. A. (1991) Role of phospholipase in generating lipid second messengers in signal transduction. *FASEB J.* **5**, 2068–2077.
- Hazen, S. L. and Gross, R. W. (1993) The specific association of a phosphofructokinase isoform with myocardial calcium-independent phospholipase A₂. *J. Biol. Chem.* **268**, 9892–9900.
- Hazen, S. L., Stuppy, R. J. and Gross, R. W. (1990) Purification and characterization of canine myocardial cytosolic phospholipase A₂. *J. Biol. Chem.* **265**, 10622–10630.
- Heinrikson, R. L., Krueger, E. T. and Keim, P. S. (1977) Amino acid sequence of phospholipase A₂ from the venom of *Crotalus adamanteus*. *J. Biol. Chem.* **252**, 4913–4921.
- Huh, D. H., Kang, M. S., Sohn, D. H., Na, D. S. and Kim, D. K. (1998) Enhancement of a liver form of cytosolic phospholipase A₂ activity by methylmercury. *J. Biochem. Mol. Biol. (formerly Korean Biochem. J.)* **31**, 189–195.
- Kim, D. K. and Bonventre, J. V. (1993) Purification of a 100 kDa phospholipase A₂ from spleen, lung and kidney: antiserum raised to pig spleen phospholipase A₂ recognizes a similar form in bovine lung, kidney and platelets, and immunoprecipitates phospholipase A₂ activity. *Biochem. J.* **294**, 261–270.
- Kim, D. K., Suh P. G. and Ryu, S. H. (1991) Purification and some properties of a phospholipase A₂ from bovine platelets. *Biochem. Biophys. Res. Commun.* **174**, 89–196.
- Larsson, P. K. A., Claesson, H. E. and Kennedy, B. P. (1998) Multiple splice variants of the human calcium-independent phospholipase A₂ and their effect on enzyme activity. *J. Biol. Chem.* **273**, 207–214.
- Ma, Z., Ramanadham, S., Kempe, K., Chi, X. S., Ladenson, J. and Turk, J. (1997) Pancreatic islets express a Ca²⁺-independent phospholipase A₂ enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. *J. Biol. Chem.* **272**, 11118–11127.
- Mezna, M., Ahmad, T., Chettibi, S., Drainas, E. and Lawrence, A. J. (1994) Zinc and barium inhibit the phospholipase A₂ from *Naja naja atra* by different mechanisms. *Biochem. J.* **301**, 503–508.
- Portilla, D. and Dai, G. (1996) Purification of a novel calcium-independent phospholipase A₂ from rabbit kidney. *J. Biol. Chem.* **271**, 15451–15457.
- Ramanadham, S., Wolf, M. J., Ma, Z., Li, B., Wang, J., Gross, R. W. and Turk, J. (1996) Evidence for association of an ATP-stimulatable Ca²⁺-independent phospholipase A₂ from pancreatic islets and HIT insulinoma cells with a phosphofructokinase-like protein. *Biochemistry* **35**, 5464–5471.
- Renetseder, R., Brunie, S., Dijkstra, B. W., Drenth, J. and Sigler, P. B. (1985) A comparison of the crystal structures of phospholipase A₂ from bovine pancreas and *Crotalus atrox* venom. *J. Biol. Chem.* **260**, 11627–11634.
- Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A. and Serhan, C. N. (1987) Leukotrienes and lipoxins: structures, biosynthesis and biological effects. *Science* **237**, 1171–1176.
- Sirois, P. (1987) Pharmacology of the leukotrienes. *Adv. Lipid Res.* **21**, 79–101.
- Sturk, A., Cate, W. T., Hosford, D., Mencia-Huerta, J. M. and Braquet, P. (1989) The synthesis, catabolism, and pathophysiological role of platelet-activating factor. *Adv. Lipid Res.* **23**, 219–274.
- Tang, J., Kriz, R. W., Wolfman, N., Shaffer, M., Seehra, J. and Jones, S. S. (1997) A novel cytosolic calcium-independent phospholipase A₂ contains eight ankyrin motifs. *J. Biol. Chem.* **272**, 8567–8575.

- Thomson, F. J. and Clark, M. A. (1995) Purification of a phosphatidic-acid-hydrolysing phospholipase A₂ from rat brain. *Biochem. J.* **306**, 305–309.
- Tischfield, J. A. (1997) A reassessment of the low molecular weight phospholipase A₂ gene family in mammals. *J. Biol. Chem.* **272**, 17247–17250.
- Wang, R., Dodia, C. R., Jain, M. K. and Fisher, A. B. (1994) Purification and characterization of a calcium-independent acidic phospholipase A₂ from rat lung. *Biochem. J.* **304**, 131–137.
- Yoshihara, Y. and Watanabe, Y. (1990) Translocation of phospholipase A₂ from cytosol to membranes in rat brain induced by calcium ions. *Biochem. Biophys. Res. Commun.* **170**, 484–490.